Table 2 Selected examples of investigations where the anti-tumor agent was protected by an NP during transport through the body and where the antineoplastic effect was expressed prolonged survival
From: NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?
Nanoparticle | Targeting ligand | Therapeutic agent | Tumor | Animal | Ref. |
|---|---|---|---|---|---|
Polymer | Biotin | Paclitaxel + tariquidar | “transformed murine” | Mice | [153] |
Polymer | None | Dox/curcumin | Four human malignancies | Mice | [265] |
Liposome | Peptide | Dox | Human neuroblastoma | Mice | [266] |
Chitosan-NP | mirRNA | Paclitaxel | Human ovarian cancer | Mice | [267] |
Polymer | Local injector | Dithiazanin | MGB | Rats | [268] |
Polymer | Abs, vs ABC G2 | Paclitaxel + siRNA | Human breast cancer | Mice | |
Polymer | None stated | Dox + Mitomyzin | Human breast cancer | Mice | [269] |
Polymer | Photodynamic and chemotherapy | Dox | Human breast cancer | Mice | [270] |